Kyorin Pharmaceutical Co., Ltd. (杏林製薬株式会社) is a Japanese pharmaceutical company headquartered in Tokyo. Founded in 1923, it researches, develops, manufactures, and markets prescription drugs, generic medicines, over-the-counter products, and diagnostics primarily in Japan and internationally.
Key products include Flutiform and Kipres for asthma and respiratory conditions, Pentasa for ulcerative colitis and Crohn's disease, Uritos for overactive bladder, Lasvic as a quinolone antibacterial agent, and others such as Desalex (antiallergic), Mucodyne (mucoregulator), and disinfectants like Rubysta and Milton. The company employs around 2,000 people and is listed on the Tokyo Stock Exchange (4569.T).
In April 2023, Kyorin Holdings, Inc. merged with its subsidiary and adopted the name KYORIN Pharmaceutical Co., Ltd. It maintains subsidiaries for generic drugs (KYORIN Rimedio) and manufacturing (KYORIN Pharmaceutical Group Facilities).
None yet. When a new project in the record names Kyorin Pharmaceutical Co., Ltd. as owner, partner or investor, it shows here.
Exclusive license grants development and commercialization rights with upfront, milestone and sales payments plus royalties. Partners will combine discovery compounds and R&D to accelerate treatments.
